共 322 条
[1]
Prieto M(1999)High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes Hepatology 29 250-256
[2]
Berenguer M(2004)Fibrosis progression after liver transplantation in patients with recurrent hepatitis C J Hepatol 41 830-836
[3]
Rayon JM(2003)The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients Liver Transpl 9 S28-34
[4]
Cordoba J(2008)Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation Am J Transplant 8 679-687
[5]
Arguello L(2014)Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: “a flood of opportunity” Am J Transplant 14 994-1002
[6]
Carrasco D(2017)Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience J Gastroenterol 52 986-991
[7]
Garcia-Herola A(2017)Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation Hepatol Res 47 1147-1154
[8]
Olaso V(2015)Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report Transplant Proc 47 809-814
[9]
De Juan M(2014)Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation Hepatol Res 44 1259-1264
[10]
Gobernado M(2016)Rapid Virological Response After Early Treatment with a Combined Therapy of Ledipasvir and Sofosbuvir in HCV Genotype 4 After Living Donor Liver Transplantation in a HCC Downstaged Patient: Case Report and Review of the Literature Am J Case Rep 17 672-675